Skip to main content
. 2021 May 3;12:2496. doi: 10.1038/s41467-021-22911-9

Fig. 1. Systemic injection of osanetant given after 30 min of fear acquisition impairs memory consolidation in adult males and enhances it in females, especially during proestrus.

Fig. 1

a Schematic representation of the Tac2 pathway. b Experimental assessment of fear memory consolidation procedure. c Effect in the fear memory test 24 h after administration of osanetant (5 mg/Kg, ip) or vehicle 30 min after fear acquisition (FA) in adult males (n = 13 per group) (p = 0.036). d Effect in the fear memory test 24 h after administration of osanetant (5 mg/kg, ip) or vehicle 30 min after FA in adult females (n = 32 per group) (p = 0.014). This experiment was replicated three times with similar results (see Source Data file). Main effect treatment, main effect CS, main effect Sex and interactions were analyzed using two-way repeated measures ANOVA. e Effect in the fear memory test 24 h after administration of osanetant (5 mg/Kg, ip) or vehicle 30 min after FA in adult females divided by their estrous cycle on the FA and drug administration day in proestrus (n = 7 per group) (p = 0.004), (f) estrus (vehicle: n = 7; osanetant: n = 8), (g) metestrus (vehicle: n = 5; osanetant: n = 6) or (h) diestrus (vehicle: n = 11; osanetant: n = 13). The effect of the treatment for each estrous cycle stage was analyzed using one-way repeated measures ANOVA. Data are expressed as mean ± SEM. *p ≤ 0.05 **p ≤ 0.01 vs. vehicle. Asterisks indicate a statistically significant main effect treatment in repeated measures ANOVA.